Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE

EFAVIRENZ;LAMIVUDINE;TENOFOVIR DISOPROXIL FUMARATE

Standard Dose
600MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE is listed in Drugs@FDA under application 204568 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient EFAVIRENZ;LAMIVUDINE;TENOFOVIR DISOPROXIL FUMARATE Form and strength TABLET; ORAL - 600MG Sponsor CIPLA Submission history Latest submission status date: 2013-12-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE is listed in Drugs@FDA under application 204568 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient EFAVIRENZ;LAMIVUDINE;TENOFOVIR DISOPROXIL FUMARATE Form and strength TABLET; ORAL - 600MG Sponsor CIPLA Submission history Latest submission status date: 2013-12-30 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.